Factors in plasma and platelets do not fully account for the proliferation of smooth muscle cells in vascular injury, implying that additional factors are involved. Recently, we and others have observed that vascular injury regulates basic fibroblast growth factor, suggesting a further role for this pleiotropic factor. We report here that injury of rat arteries leads to an increase in fibroblast growth factor receptors in vascular smooth muscle cells. This up-regulation makes smooth muscle cells susceptible, in vitro and in vivo, to the lethal effects of a conjugate of basic fibroblast growth factor with the ribosome inactivator saporin. Saporin alone has no effect, whereas the conjugate kills proliferating, but not quiescent, smooth muscle cells in vitro. In vivo, one to three doses inhibit neointimal proliferation but have no apparent effect on the uninjured artery. Thus, the up-regulation of fibroblast growth factor receptors in vascular injury suggests new therapeutic possibilities for such refractory conditions as restenosis following balloon angioplasty.
METHODS
Materials. Recombinant bFGF and recombinant saporin (SAP) were cross-linked and purified by heparin-Sepharose chromatography as described (13) .
Cell Culture. SMCs were isolated by enzymatic digestion of the medial layers of rat aorta obtained from 7-week-old male Sprague-Dawley rats as described (10) , to yield the characteristic multilayered hill and valley cultures with phase-dense cytoplasm and smooth muscle al actin immunoreactivity (clone 1A4; Sigma). The cells were grown in medium 199 in 10% fetal bovine serum (FBS; Biofluids, Rockville, MD) without bFGF and split weekly at a 1:4 ratio. Assays for protein and DNA synthesis and cell proliferation are described in the figure legends.
Immunohistochemistry. Two polyclonal antibodies were raised in rabbits using synthetic peptide replicates of two domains deduced from the cDNA of FGFR-1 (flg). A sequence at the C terminus (CSSGEDSVFSHEPLPEEP) located beyond the tyrosine kinase domain was chosen for the intracellular domain as it has predicted antigenicity and 100% homology with the reported chicken (14) , mouse (15) , and human (16) FGFR-1. The corresponding region of FGFR-2 (bek), FGFR-3, and FGFR-4 has 72%, 61%, and 78% homology, respectively. Western blotting with this antiserum (R129) reveals a protein in embryonic and brain tissues that is not seen when the antiserum is preadsorbed with excess peptide immunogen. A second antiserum (R131) was raised to a peptide whose sequence (RITGEEVEVRDR) derives from the first (outermost) immunoglobulin-like loop of FGFR-1. It has 8%, 9%, and 18% homology with the corresponding regions of FGFR-2, FGFR-3, and FGFR-4, respectively, and gives similar results in immunostaining as the antibody to the intracellular domain.
The immunostaining was performed as described (17) .
Briefly, formalin-fixed, 6 -Ium, paraffin sections of rat carotid arteries were etched with hyaluronidase, blocked, and stained by the indirect alkaline phosphatase method. Nonimmune serum and peptide adsorption, and virtual absence of stain in A431 cells lacking FGFRs, served as negative controls. Staining of rat brain served as positive control. Binding Assays. Membranes were prepared from normal 7-week-old rat aortas and aortas at 24 and 48 h after balloon injury (see below), as described (18) . Protein levels were determined using the Pierce protein assay according to manufacturer's instructions with bovine serum albumin as a standard. Samples containing 20, 40, 60 , and 80 gg of protein in 100 Al of 20 mM Hepes (pH 7.4), 1 ttg of leupeptin per ml, 2 mM EDTA, 20 kallikrein inhibitor units of aprotinin per ml, 1 mM phenylmethylsulfonyl fluoride, 250 mM sucrose, and 0.2% bovine serum albumin (HB) containing 200 pM of 125I-labeled bFGF were incubated in a 1.5-ml microcentrifuge tube for 30 min at 23TC, 1.0 ml of ice-cold HB/2 M NaCl was added, samples were centrifuged at 16 ,000 x g, supernatant was aspirated, and 1.0 ml of ice-cold HB was added, followed by centrifugation and aspiration of the supernatant. The tubes containing the pellets were then assayed for radioactivity in a y counter. Background cpm obtained in the absence of membrane protein were '20% of the total cpm and were subtracted from the samples. to digestion in Protosol (New England Nuclear) according to the manufacturer's instructions and liquid scintillation spectroscopy in Ionic-Fluor (Packard), corrected by quench curves. Despite plasma levels of 0.8 ng/ml 24 h after injection (estimated by mixing 50 ng of 125I-labeled bFGF in 950 ng of unlabeled bFGF and assay of trichloroacetic acid-insoluble cpm in a 'y counter), a level giving nearly maximal mitogenic effect in vitro, only 0.33% of the bFGF tracer bound to the heart and 42% of this was displaceable by heparin. There was no effect on thymidine incorporation in the heart (B). Similar results were obtained when heart sections were embedded in paraffi and subjected to autoradiography using NTB-2 emulsion. Labeled capillary nuclei were counted in two sections of each of four rats treated with bFGF and in two rats treated with saline. The average (±SD) number of labeled nuclei per mm2 in the bFGF-treated rats was 11.4 + 5.3 vs. 12.6 + 4.0 for the saline-treated rats (P > 0.1 by two-tailed t test). In contrast (A), the s.c. tissue injured by repeated injections revealed more local [3H]thymidine uptake when injected with bFGF than with saline. (c) In vivo autoradiographic evidence that FGFRs are expressed after vascular injury. Adult rats were subjected to balloon dilation of the carotid artery and injected i.v. 2 days later with 60 ng of either mitogenically active or heat-denatured (90'C, 1 h) 17'I-labeled bFGF (105 cpm/ng iodinated as described) with or without 10 pg of unlabeled bFGF; this was followed 1 h later by i.v. heparin (Fig. ic) , confirming the immunoreactivity pattern in the SMCs of the injured arteries (Fig. ld) . Thus, injury to the vasculature induces the expression of FGFRs.
Recognizing that the activities of bFGF appear to be limited by the expression of its receptor, we evaluated the potential use of a receptor-specific cytocidal agent to control SMC proliferation. To this end, we examined the effects of a conjugate protein consisting of bFGF and SAP, a plantderived enzyme that inactivates ribosomes by cleaving adenine from ribose in the 28S RNA of the 60S subunit (22) .
In vitro studies (Fig. 2) 10% of cells remain viable, as indicated by exclusion of trypan blue. Moreover, 10 nM FGF-SAP had no effect in nonproliferating SMCs (not shown).
It is particularly remarkable that the initial response to low concentrations of FGF-SAP (0.1-1 nM) includes an increase in protein and DNA synthesis (Fig. 2) . Although the reason for this effect is not clear, we have attributed this biphasic response to the different potencies and different mechanisms of action of FGF (signal transduction) and SAP (enzymatic action).
We tested FGF-SAP in an in vivo model where we had observed increased FGFR expression (Fig. 3) . Under these conditions, when FGF-SAP (1-10 pg/kg) is locally applied, there is a concomitant death of most medial SMCs and a 75% reduction in neointimal cell number 14 days after injury (Fig.   3a) . Rats given 100 pg/kg i.v. at 24, 48, and 72 h after injury had 83% less neointimal accumulation at 7 days than SAP-or saline-treated controls (Fig. 3 c and d) . However, there were some areas of apparent SMC death in the medial layer, implying a risk of aneurysm or rupture. The uninjured right carotids were histologically normal, but an 8% body weight loss was noted, suggesting systemic toxicity.
Rats given i.v. FGF-SAP as a single 75 pg/kg dose 24 h after balloon injury had 24% less neointimal proliferation atthan do SMCs, are spared the cytotoxic actions of FGF-SAP (unpublished data).
DISCUSSION
In this report, we describe evidence that balloon injury to the rat carotid artery induces high-affimity receptors for bFGF in the injured loci. Using this knowledge, we reasoned that the up-regulation ofreceptors permits the use ofligands like bFGF to act as specific vectors to carry toxins like SAP to eliminate specific cell populations. On this basis, we propose that FGFR-mediated cytotoxicity for SMCs may provide a strategy for developing therapies based on molecular atherectomy.
SMC migration, proliferation, and secretion of matrix are the dominant cellular events in restenosis following balloon angioplasty and are also prominent features of atherosclerosis, transplant rejection, and some forms of hypertension and Kaposi sarcoma (for reviews, see refs. 1 and 2). These processes have been largely refractory to clinical therapies, perhaps due to the development of autonomous SMC clones and/or to redundancy of mitogens. Numerous plasma factors and factors derived from macrophages, platelets, endothelial cells, and SMCs themselves have been implicated in this process (for reviews, see refs. 1 and 2). bFGF is a chemoattractant and a mitogen for vascular SMCs [though reports to the contrary should also be noted (23, 24) ]. We and others (11, 12, 25) have shown that infusions of bFGF enhance SMC proliferation following balloon injury, whereas neutralizing antibodies to bFGF inhibit DNA synthesis, at least initially. Since bFGF is thought to be stored in cells and in their extracellular matrix, Lindner and Reidy (12) have proposed that cellular injury releases bFGF (which lacks a signal peptide), thereby contributing to SMC proliferation by an autocrine and/or paracrine mechanism.
This implies that FGFRs are present in the normal vessel (permitting a rapid response to released bFGF) or are induced shortly after balloon injury. In fact, the distribution of receptors for bFGF in normal adult tissues has not been settled. Some investigators have reported FGFR-1/flg to be present in embryonic tissues but absent in adult tissues other than brain (15, (26) (27) (28) (29) , whereas others have found these transcripts to be widespread in adult tissues (30) (31) (32) . Recently, four more members of this tyrosine kinase family have been described and reported to exhibit some tissuespecific adult expression (33, 34) . These receptors bind acidic FGF with high affinity and all but one of them bind bFGF and probably other FGF family members as well (31) . The reasons for this unparalleled degree of redundancy are not known. Multiple alternative splicing patterns have been reported (35) (36) (37) . These may confer cell specificity but they also can lead to false negative results with antibody or cRNA probes. Moreover, there are several reports of transcripts that appear to encode secreted extracellular domains capable of binding bFGF and acidic FGF (35) . Finally, binding of bFGF appears to be subject to post-translational regulation (38) . Not surprisingly perhaps, a developmentally regulated discrepancy between FGFR-1 mRNA and binding of bFGF has been described (39) . For these reasons we focused our initial studies on binding of radiolabeled bFGF. Little specific binding was detected in normal adult vessels, with embryonic tissue and normal adult brain serving as positive controls. Balloon injury led to the appearance of binding sites for bFGF within 24 h. Because such binding could conceivably be nonfunctional (e.g., reflecting binding to secreted extracellular domains of FGFRs or to heparan sulfate proteoglycans on the cell surface), we also utilized functional assays. Thus, i.v. bFGF had no effect on DNA synthesis in normal uninjured vessels (suggesting few FGFRs on the lumenal surface of endothelial cells, poor penetration to SMCs, and/or "distal" inhibition of FGF's effects) but accelerated SMC proliferation following balloon injury. Similarly, FGF-SAP killed proliferating SMCs in balloon-injured arteries but had no effect on contralateral normal arteries in the same animal. It will be important to establish optimal dosing schedules and to determine whether this treatment can prevent SMC migration and proliferation or merely cause a delay. The 
